106 related articles for article (PubMed ID: 28666202)
1. The impact of cocaine use in patients enrolled in opioid agonist therapy in Ontario, Canada.
Franklyn AM; Eibl JK; Gauthier GJ; Pellegrini D; Lightfoot NE; Marsh DC
Int J Drug Policy; 2017 Oct; 48():1-8. PubMed ID: 28666202
[TBL] [Abstract][Full Text] [Related]
2. The impact of benzodiazepine use in patients enrolled in opioid agonist therapy in Northern and rural Ontario.
Franklyn AM; Eibl JK; Gauthier G; Pellegrini D; Lightfoot NE; Marsh DC
Harm Reduct J; 2017 Jan; 14(1):6. PubMed ID: 28122579
[TBL] [Abstract][Full Text] [Related]
3. A cohort study evaluating the association between concurrent mental disorders, mortality, morbidity, and continuous treatment retention for patients in opioid agonist treatment (OAT) across Ontario, Canada, using administrative health data.
Morin KA; Eibl JK; Gauthier G; Rush B; Mushquash C; Lightfoot NE; Marsh DC
Harm Reduct J; 2020 Jul; 17(1):51. PubMed ID: 32703310
[TBL] [Abstract][Full Text] [Related]
4. Evaluating the Effectiveness of First-Time Methadone Maintenance Therapy Across Northern, Rural, and Urban Regions of Ontario, Canada.
Eibl JK; Gomes T; Martins D; Camacho X; Juurlink DN; Mamdani MM; Dhalla IA; Marsh DC
J Addict Med; 2015; 9(6):440-6. PubMed ID: 26484843
[TBL] [Abstract][Full Text] [Related]
5. The impact of cannabis use on patients enrolled in opioid agonist therapy in Ontario, Canada.
Franklyn AM; Eibl JK; Gauthier GJ; Marsh DC
PLoS One; 2017; 12(11):e0187633. PubMed ID: 29117267
[TBL] [Abstract][Full Text] [Related]
6. Measuring treatment attrition at various stages of engagement in Opioid Agonist Treatment in Ontario Canada using a cascade of care framework.
Tahsin F; Morin KA; Vojtesek F; Marsh DC
BMC Health Serv Res; 2022 Apr; 22(1):490. PubMed ID: 35413980
[TBL] [Abstract][Full Text] [Related]
7. Gender-specific predictors of retention and opioid abstinence during methadone maintenance treatment.
Levine AR; Lundahl LH; Ledgerwood DM; Lisieski M; Rhodes GL; Greenwald MK
J Subst Abuse Treat; 2015 Jul; 54():37-43. PubMed ID: 25795601
[TBL] [Abstract][Full Text] [Related]
8. Long-term retention in Office Based Opioid Treatment with buprenorphine.
Weinstein ZM; Kim HW; Cheng DM; Quinn E; Hui D; Labelle CT; Drainoni ML; Bachman SS; Samet JH
J Subst Abuse Treat; 2017 Mar; 74():65-70. PubMed ID: 28132702
[TBL] [Abstract][Full Text] [Related]
9. Retention in Georgia opioid substitution therapy program and associated factors.
Ruadze E; Todadze K
Harm Reduct J; 2016 Dec; 13(1):35. PubMed ID: 27931232
[TBL] [Abstract][Full Text] [Related]
10. Concurrent psychiatry for patients enrolled in opioid agonist treatment: a propensity score matched cohort study in Ontario Canada.
Morin KA; Eibl JK; Caswell JM; Gauthier G; Rush B; Mushquash C; Lightfoot NE; Marsh DC
Subst Abuse Treat Prev Policy; 2019 Jun; 14(1):29. PubMed ID: 31242949
[TBL] [Abstract][Full Text] [Related]
11. The effectiveness of telemedicine-delivered opioid agonist therapy in a supervised clinical setting.
Eibl JK; Gauthier G; Pellegrini D; Daiter J; Varenbut M; Hogenbirk JC; Marsh DC
Drug Alcohol Depend; 2017 Jul; 176():133-138. PubMed ID: 28535455
[TBL] [Abstract][Full Text] [Related]
12. The impact of benzodiazepine use on methadone maintenance treatment outcomes.
Brands B; Blake J; Marsh DC; Sproule B; Jeyapalan R; Li S
J Addict Dis; 2008; 27(3):37-48. PubMed ID: 18956528
[TBL] [Abstract][Full Text] [Related]
13. Factors associated with dropout among patients in opioid maintenance treatment (OMT) and predictors of re-entry. A national registry-based study.
Bukten A; Skurtveit S; Waal H; Clausen T
Addict Behav; 2014 Oct; 39(10):1504-9. PubMed ID: 24960556
[TBL] [Abstract][Full Text] [Related]
14. Patterns of abstinence or continued drug use among methadone maintenance patients and their relation to treatment retention.
White WL; Campbell MD; Spencer RD; Hoffman HA; Crissman B; DuPont RL
J Psychoactive Drugs; 2014; 46(2):114-22. PubMed ID: 25052787
[TBL] [Abstract][Full Text] [Related]
15. A national study of the retention of Irish opiate users in methadone substitution treatment.
Mullen L; Barry J; Long J; Keenan E; Mulholland D; Grogan L; Delargy I
Am J Drug Alcohol Abuse; 2012 Nov; 38(6):551-8. PubMed ID: 22747484
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of 6 remote First Nations community-based buprenorphine programs in northwestern Ontario: Retrospective study.
Mamakwa S; Kahan M; Kanate D; Kirlew M; Folk D; Cirone S; Rea S; Parsons P; Edwards C; Gordon J; Main F; Kelly L
Can Fam Physician; 2017 Feb; 63(2):137-145. PubMed ID: 28209683
[TBL] [Abstract][Full Text] [Related]
17. Psychiatric Comorbidity and Substance Use Outcomes in an Office-Based Buprenorphine Program Six Months Following Hurricane Sandy.
Tofighi B; Grossman E; Goldfeld KS; Williams AR; Rotrosen J; Lee JD
Subst Use Misuse; 2015; 50(12):1571-8. PubMed ID: 26623697
[TBL] [Abstract][Full Text] [Related]
18. Negative Impact of Amphetamine-Type Stimulant Use on Opioid Agonist Treatment Retention in Ontario, Canada.
Morin KA; Vojtesek F; Acharya S; Marsh DC
Front Psychiatry; 2021; 12():782066. PubMed ID: 34987430
[No Abstract] [Full Text] [Related]
19. A Retrospective Cohort Study Comparing In-Person and Telemedicine-Based Opioid Agonist Treatment in Ontario, Canada, Using Administrative Health Data.
Morin KA; Parrotta MD; Eibl JK; Marsh DC
Eur Addict Res; 2021; 27(4):268-276. PubMed ID: 33706309
[TBL] [Abstract][Full Text] [Related]
20. Evidence of increased Fentanyl use during the COVID-19 pandemic among opioid agonist treatment patients in Ontario, Canada.
Morin KA; Acharya S; Eibl JK; Marsh DC
Int J Drug Policy; 2021 Apr; 90():103088. PubMed ID: 33385974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
